Forte Biosciences enters ATM equity sales agreement for up to $25M

Forte Biosciences, Inc.

Agreement with Ladenburg Thalmann allows sale of up to $25M common stock; initial prospectus supplement covers $7M.
Commission of 3.0% of gross proceeds payable to Ladenburg for at-the-market sales.
Net proceeds to be used for general corporate purposes and funding of clinical programs.
Company not obligated to sell any shares; sales will be at prevailing market prices.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.